Lisata Secures New Composition of Matter Patent for Certepetide

By Daniella Parra

Lisata Therapeutics said it has been granted a new composition of matter patent for its lead drug candidate, certepetide, offering the highest level of IP protection by covering the drug’s unique chemical structure, how it’s made, and how it’s used to treat solid tumor cancers, they said.

Certepetide is an investigational peptide drug developed to improve the delivery of anti-cancer therapies into solid tumors, the company said.

“This new patent marks a key milestone, significantly boosting the value of both certepetide and the Company by delaying generic encroachment for essentially the next two decades,” stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata. “[It] greatly strengthens our negotiating position with potential partners, increasing the potential for sustained growth and value creation for our shareholders.”